(Q35037333)

5 August 2017

1 reference

title

New developments in the treatment of invasive cervical cancer (English)

1 reference

5 August 2017

2

Bradley J Monk

1 reference

5 August 2017

Samuel S Im

1

1 reference

5 August 2017

publication date

1 December 2002

1 reference

Obstetrics and Gynecology Clinics of North America

5 August 2017

published in

1 reference

5 August 2017

volume

29

1 reference

5 August 2017

issue

4

1 reference

5 August 2017

page(s)

659-672

1 reference

Human papillomavirus vaccines for cervical cancer

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Estimates of the worldwide incidence of 25 major cancers in 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Estimates of the worldwide mortality from 25 cancers in 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group stud

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Microinvasive Carcinoma of the Cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Prospective management of stage IA(1) cervical adenocarcinoma by conization alone to preserve fertility: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Lymphatic mapping and sentinel lymphadenectomy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Technical details of intraoperative lymphatic mapping for early stage melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Sentinel node procedure in Ib cervical cancer: a preliminary series

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Patterns of radiotherapy practice for patients with squamous carcinoma of the uterine cervix: patterns of care study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Advances in the treatment of cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Human papillomaviruses and cervical neoplasia: a model for carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Angiogenesis in cervical neoplasia: microvessel quantitation in precancerous lesions and invasive carcinomas with clinicopathological correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Different angiogenic pathways in human cervical cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Tumor angiogenesis in stage IB cervical cancer: correlation of microvessel density with survival

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Erythropoietin increases hemoglobin during radiation therapy for cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Erythropoietin for chemotherapy patient refusing blood transfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900024-4

7 January 2021

10.1016/S0889-8545(02)00024-4

Identifiers

DOI

1 reference

5 August 2017

1 reference